MEDICINOVA INC 8-K

What Happened

• MediciNova, Inc. announced on Feb 20, 2026 (Japanese Standard Time) that it filed a "Kessan Tanshin" (Tanshin) with the Tokyo Stock Exchange containing the company's preliminary, unaudited financial results for the year ended December 31, 2025.
• The company attached an English translation of the Tanshin as Exhibit 99.1 to the Form 8-K. The audited financial statements for the year ended December 31, 2025 are not yet complete.

Key Details

• Filing date: February 20, 2026 (Japanese Standard Time). Reporting period: year ended December 31, 2025.
• Results disclosed in the Tanshin are preliminary and unaudited; they are subject to completion of year‑end closing procedures and the company’s audit.
• MediciNova’s independent registered public accounting firm has not completed its audit and expresses no opinion or assurance on the preliminary numbers.
• The company warns these preliminary results may change and those changes could be material; the information is being furnished (not “filed”) under the Exchange Act.

Why It Matters

• For investors, these are early, unaudited earnings/results—useful for a first look at 2025 performance but not final. Any investment decisions should account for the possibility of material adjustments when the audited financial statements are released.
• The absence of a completed audit means key figures like revenue, expenses, and net income reported in the Tanshin could change; monitor forthcoming audited results and company updates for confirmed financials.